Regulatory & Legal

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Duff & Phelps's fund maintains its payout, but the real story is its bet on an AI-driven energy boom. We unpack the strategy and its risks.

Erie Indemnity boosts its dividend by 7.1%, but a deeper look reveals a unique and legally challenged fee structure driving its profitability.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

PG&E's new grid tech does more than keep lights on; it's a vital upgrade for healthcare resilience, wildfire prevention, and safety in a changing climate.

New journalism awards tackle AI's risks and Indigenous health gaps, revealing how media innovation aims to build a healthier, more equitable Canada.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

A 150-year-old agricultural giant is pivoting its strategy, using a sophisticated data model to link sustainability directly to its bottom line.

As the AI skills gap widens, a new framework aims to move companies from pilot purgatory to true adoption by training everyone, not just tech experts.

After a costly restatement process, Next Bridge Hydrocarbons shifts its drilling focus. But can a new strategy resolve its unique shareholder crisis?

GWI's new AI award signals a major shift. Discover how AI is reshaping the water sector and which companies are poised to lead this tech-driven transformation.

A hedge fund's disclosure reveals a puzzling short position and a fresh stock purchase in American Axle, hinting at a high-stakes arbitrage play.

A regulatory filing uncovers a major bank's intricate derivatives strategy in a £2.3bn takeover, raising questions about market transparency.

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

A major hedge fund's move in a $2.4B semiconductor deal reveals a critical truth: the future of precision medicine is built on high-speed data infrastructure.

A UK regulatory filing reveals a hedge fund's bet against Qualcomm, questioning its major takeover and highlighting the surprising global reach of financial oversight.

From a Greenland mine to a Romanian refinery, a tech breakthrough is de-risking a vital new source of rare earths for the West's defense and green tech.

Hong Kong's JM Group raised $15M in a wild NYSE debut. We look past the volatility to see what this IPO reveals about global supply chains and risk.

Hedge fund Balyasny reveals a 1.26% economic stake in Just Group via derivatives, shining a light on the complex strategies at play in its takeover.